SALE ON NOW! PROMOTIONS

Close Notification

Your cart does not contain any items

Cell-based Immunotherapies for Cancer

Alok K. Mishra Sunil K. Malonia

$539.95   $431.65

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Springer International Publishing AG
25 June 2025
This book explores the rapidly evolving field of cancer immunotherapy, which focuses on harnessing the immune system's power to combat cancer. As traditional treatments like chemotherapy and radiation therapy often have significant side effects and may not be effective for all cancer types, immunotherapy offers a promising alternative.

Among the most notable advancements in this field are cell-based therapies, which involve modifying a patient’s own immune cells or engineering specialized cells to enhance their ability to target cancer. Key approaches include chimeric antigen receptor (CAR) T-cell therapy, tumor-infiltrating lymphocyte (TIL) therapy, and dendritic cell (DC)-based therapy.

Providing a comprehensive overview of these therapies, this book explores their scientific foundations, recent developments, clinical applications, and associated challenges. It also discusses emerging immunotherapeutic strategies, the commercial landscape, and future research directions.

A valuable resource for researchers, clinicians, and industry professionals involved in cancer treatment, this book also serves as an informative reference for students and academics in biology, biotechnology, immunology, and related disciplines seeking a deeper understanding of cancer immunotherapy.
Edited by:   ,
Imprint:   Springer International Publishing AG
Country of Publication:   Switzerland
Dimensions:   Height: 235mm,  Width: 155mm, 
ISBN:   9783031886942
ISBN 10:   3031886941
Pages:   395
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active

Dr. Alok K. Mishra is a biotechnology expert specializing in immune-oncology and cancer drug discovery. He earned his Ph.D. in Biological Sciences from Central Drug Research Institute, India, studying mycobacterial genetics and immuno-biology. He completed his postdoctoral training in the laboratory of renowned cancer biologist Dr. Michael R. Green at the University of Massachusetts Chan Medical School, USA, where he investigated regulatory networks of innate immune checkpoints and oncogenic drivers in cancer. Currently, Dr. Mishra is a Research Scientist in the Department of Hematopoietic Biology and Malignancy at MD Anderson Cancer Center, USA, focusing on tumor–immune cell interactions and the development of targeted and cellular immunotherapies for solid malignancies. His research has led to the filing of two international patents on formulating novel ovarian cancer treatments and selective targeting of cancer stem cells in glioblastoma. Dr. Mishra has also published in high-impact journals and serves as a peer reviewer and associate editor for leading biomedical Journals. As a corresponding editor of this book, he brings scientific expertise and a commitment to innovation, curating cutting-edge content that addresses key challenges in cancer biology and immunotherapy. His work holds significant translational potential, aiming to improve cancer patient outcomes and advance cancer immunotherapies. Dr. Sunil K. Malonia is an accomplished cancer biologist and an instructor/faculty member in the Department of Molecular, Cell, and Cancer Biology at UMass Chan Medical School, USA. He earned his PhD in Biotechnology from the National Center for Cell Science in India, where his research focused on the precise regulation of gene expression by cis-regulatory DNA elements in cancer. He completed his postdoctoral research at the Howard Hughes Medical Institute, University of Massachusetts Medical School, where he investigated the epigenetic regulation of tumor suppressor genes and oncogenes in various cancers. Dr. Malonia’s current research program focuses on identifying therapeutically targetable pathways in cancer, with a particular emphasis on understanding the molecular mechanisms of cancer progression, chemoresistance, and immune evasion. Some of his work has led to the identification of novel drug targets in cancer and the development of promising therapeutic strategies. An active contributor to the scientific community, Dr. Malonia has authored numerous research publications and review articles and serves as a peer reviewer for multiple scientific journals. As the senior editor of this book, he brings a unique blend of scientific expertise and translational insight, particularly in immuno-oncology and immunotherapy. His leadership and editorial contributions reflect his steadfast commitment to advancing cancer research and fostering innovative immune therapeutic approaches.

See Also